2016


To access this material please log in or register

Register Authorize
2016/№1

Cardiotoxicity of chemotherapy

Seliverstova D. V., Evsina O. V.
State Budgetary Educational Institution of Higher Professional Education, “Ryazan State Medical University” of the RF Ministry of Health Care, Vysokovoltnaya 9, Ryazan 390026

Keywords: cardiotoxicity, cardiovascular pathology, chemotherapy

DOI: 10.18087/rhj.2016.1.2115

Progress in diagnostics and treatment of malignancies has resulted in a considerable decrease in mortality. However, chemotherapy leads to cardiovascular complications. The objective of researchers is finding a balance between the effect of antitumor therapy and risk for the cardiovascular system.
  1. Радюкова И. М., Нечаева Г. И., Кореннова О. Ю., Друк И. В., Меркулов В. Н., Качур И. Г. и др. Эндотелиальная дисфункция как патогенетический фактор повреждения внутренних органов при полихимиотерапии рака молочной железы. Сибирский медицинский журнал (г. Томск). 2012;27 (1):85–9.
  2. Конончук Н. Б., Митьковская Н. П., Абрамова Е. С. и др. Кардиотоксичность, индуцированная химиотерапией рака молочной железы: факторы риска, патогенез. Медицинский журнал (Минск). 2013;3 (45):4–7.
  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62 (1):10–29.
  4. Суринов А. Е. Заболеваемость населения социально-значимыми болезнями. Российский статистический ежегодник. 2014: Стат. сб. Росстат. – Р76 – М., 2014. – 693 с.
  5. Суринов А. Е. Умершие по основным классам причин смерти. Российский статистический ежегодник. 2014: Стат. сб. Росстат. – Р76 – М., 2014. – 693 с.
  6. Суринов А. Е. Смертность населения по причинам смерти в 2013 году. Российский статистический ежегодник. 2014: Стат. сб. Росстат. – Р76 – М., 2014. – 693 с.
  7. Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. – М.: Издательская группа РОНЦ, 2014. – 226с.
  8. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005 Oct 20;23 (30):7685–96.
  9. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006 Feb;33 (1):2–14.
  10. Стенина М. Б., Гладков О. А., Копп М. В., Королева И. А., Малыгин С. Е., Портной С. М. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. М., 2014; 360–368.
  11. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013 Apr;34 (15):1102–11.
  12. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005 May 31;111 (21):2837–49.
  13. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 5;102 (9):596–604.
  14. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010 May;23 (5):460–8.
  15. Kleiman NS, Lehane DE, Geyer CE Jr, Pratt CM, Young JB. Prinzmetal’s angina during 5‑fluorouracil chemotherapy. Am J Med. 1987 Mar;82 (3):566–8.
  16. Van Halteren HK, Liem AH, Planting AS. Myocardial ischemia as a result of treatment with capecitabine. Ned Tijdschr Geneeskd. 2007 Jun 30;151 (26):1469–73.
  17. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010 Dec 9;116 (24):5377–82.
  18. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011 Sep 1;29 (25):3466–73.
  19. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15;19 (18):3852–60.
  20. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosomepositive, chronic myeloid leukaemia: 24‑month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep;12 (9):841–51.
  21. Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol. 2010 Feb 15;105 (4):522–6.
  22. Tan TC, Scherrer-Crosbie M. Cardiac complications of chemotherapy: role of imaging. Curr Treat Options Cardiovasc Med. 2014 Apr;16 (4):296.
  23. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 Apr 13;342 (15):1077–84.
  24. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al. Adjuvant trastuzumab in HER2‑positive breast cancer. N Engl J Med. 2011 Oct 6;365 (14):1273–83.
  25. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011;38 (3):263–5.
  26. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA. 1978 Oct 6;240 (15):1603–6.
  27. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978 Jun;62 (6):857–64.
  28. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008 Mar 10;26 (8):1201–3.
  29. Jurcut R, Wildiers H, Ganame J, D'Hooge J, Paridaens R, Voigt JU. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer. 2008 May;16 (5):437–45.
  30. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002 Mar 1;20 (5):1215–21.
  31. Tan-Chiu E, Yothers G, Romond E, Geyer Jr CE, Ewer M, Keefe D et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2‑overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005 Nov 1;23 (31):7811–9.
  32. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, and branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18 (12):1440–63.
  33. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979 Feb 8;300 (6):278–83.
  34. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002 Jun 5;86 (11):1697–700.
  35. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002 May;13 (5):699–709.
  36. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3‑dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol. 2012 May 15;59 (20):1799–808.
  37. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, threedimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J. 2009 Jan;30 (1):98–106.
  38. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013 Jan 8;61 (1):77–84.
  39. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010 Jul 20;28 (21):3429–36.
  40. Leitman M, Iysyansky P, Sidenko S, Shir V, Peleg E, Binenbaum M et al. Two-dimentional strain a novel software for real time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr. 2004 Oct;17 (10):1021–9.
  41. Motoki H, Koayma J, Nakazawa H, Aizawa K, Kazai H, Izawa A et al. Torsion analysis in the early detection of anthracyclin-media­ted cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012 Jan;13 (1):95–103.
  42. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012 Sep 1;5 (5):596–603.
  43. Vasu S, Hundley WG. Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Jul 31;15:66.
  44. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003 Jan;45 (1):55–75.
  45. Vasu S, Hundley WG. Understanding cardiovascular injury after treatment for cancer: an overview of current users and future directions of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Jul 31;15:66.
  46. Thompson RC, Candy RC, Lojeski EW, Ratner AV, Fallon JT, Pohost GM. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. Am Heart J. 1987 Jun;113 (6):1444–9.
  47. Wassmuth R, Lentzsch S, Erdbruegger U, Shulz-Mendger J, Doerken B, Dietz R, Friedrich MG. Subclinical cardiotoxic effects of antracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001 Jun;141 (6):1007–13.
  48. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennel DJ. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subject and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002 Jul 1;90 (1):29–34.
  49. Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr. 2011 Dec;12 (12):945–52.
  50. Chaosuwannakit N, D’Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010 Jan 1;28 (1):166–72.
  51. Eckman DM, Stacey RB, Rowe R, D’Agostino RJ, Kock ND, Sane DC et al. Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS One. 2013;8 (2):e57554.
  52. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 May 25;293 (20):2479–86.
  53. Jacobi B, Bongartz G, Partovi S, Schulte AC, Aschwanden M, Lumsden AB et al. Skeletal muscle BOLD MRI: from under­lying physiological concepts to its usefulness in clinical conditions. J Magn Reson Imaging. 2012 Jun;35 (6):1253–65.
  54. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG et al. ACCF / ACR / AHA / NASCI / SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Forceon Expert Consensus Documents. J Am Coll Cardiol. 2010 Jun 8;55 (23):2614–62.
  55. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987 Jun;82 (6):1109–18.
  56. Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol. 2013 Jun;20 (3):443–64.
  57. Cottin Y, Touzery C, Coudert B, Gilles A, Walker P, Massing JL et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J. 1995 Jan;73 (1):61–4.
  58. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011 Dec;130 (3):845–54.
  59. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and non­failing hearts. J Nucl Cardiol. 1998 Nov-Dec;5 (6):579–90.
  60. Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Nakaki M et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993 Aug;34 (8):1283–6.
  61. Kongbundansuk S, Hundley WG. Noninvasive imaging of cardiovascular injury related to the treatment of cancer. JACC Cardiovasc Imaging. 2014 Aug;7 (8):824–38.
  62. Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A et al. Detection of dose response in chronic doxorubicin mediated cell death with cardiac technetium 99m – annexin V single-photon emission computed tomography. Mol Imaging. 2008 May-Jun;7 (3):132–8.
  63. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med. 2001 Sep 27;345 (13):995–6.
  64. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S et al. Indium-111‑labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2‑positive metastatic breast cancer. J Clin Oncol. 2006 May 20;24 (15):2276–82.
  65. Гершанович М. Л. Кардиотоксичность противоопухолевых антрациклиновых антибиотиков и возможности ее предупреждения кардиоксаном (дексразоксаном) в онкологической практике. Вопросы онкологии. 2001;47 (1):23–9.
  66. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55 (3):213–20.
  67. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004 Mar 1;22 (5):820–8.
  68. Ma SF, Guan SD, Zhu Y. Effect of soybean isofl avones on heart function of rats with adriamycin-induced heart failure. Zhong Xi Yi Jie He Xue Bao. 2004 Jul;2 (4):278–80.
  69. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006 Dec 5;48 (11):2258–62.
  70. Nohria A. β-Adrenergic blockade for anthracycline – and trastuzumab-Induced cardiotoxicity is prevention better than cure? Circ Heart Fail. 2013 May;6 (3):358–61.
  71. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005 Dec 13;112 (24):3795–801.
  72. Васюк Ю. А., Школьник Е. Л., Несветов В. В., Школьник Л. Д., Варлан Г. В., Пильщиков А. В. Антрациклиновая кардиотоксичность: перспективы использования ивабрадина. Cardioсоматика. 2012;4:65–9.
  73. Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G, George J. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J. 2006 Aug;27 (15):1876–83.
  74. Jorgensen E, Bindslev L, Ripa RS, Kastrup J. Epo «cytokine-doping» of heart disease patients, will it work? Eur Heart J. 2006 Aug;27 (15):1767–8.
  75. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 (Suppl 7):vii155–66.
Seliverstova D. V., Evsina O. V. Cardiotoxicity of chemotherapy. Russian Heart Journal. 2016;15 (1):50–57

To access this material please log in or register

Register Authorize
Ru En